ABSTRACT
Despite this interpretation of the early experience, another generation has passed since the NPCP trials were initiated, without cytotoxic therapy earning a place in the routine management of patients with metastatic prostate cancer. Recent modification of chemotherapy and the introduction of prostate-specific antigen (PSA) testing that permits efficient assessment of ‘response’ have changed this perception.
